These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6114 related articles for article (PubMed ID: 31806129)

  • 21. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
    Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial.
    Lu H; Chatur S; Lee S; Inciardi RM; Abanda M; Mc Causland FR; Kalayci A; Taheri KK; Shah AM; Cikes M; Claggett BL; Prasad N; Lam CSP; O'Meara E; Wang X; McMurray JJV; Pfeffer MA; Hegde SM; Solomon SD; Skali H
    Circ Heart Fail; 2024 Oct; 17(10):e011942. PubMed ID: 39212045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Tromp J; Claggett BL; Liu J; Jackson AM; Jhund PS; Køber L; Widimský J; Boytsov SA; Chopra VK; Anand IS; Ge J; Chen CH; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Rizkala AR; Inubushi-Molessa A; Lefkowitz MP; Shi VC; McMurray JJV; Solomon SD; Lam CSP;
    Circ Heart Fail; 2021 Apr; 14(4):e007901. PubMed ID: 33866828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
    Desai AS; Vaduganathan M; Cleland JG; Claggett BL; Barkoudah E; Finn P; McCausland FR; Yilmaz MB; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Dec; 14(12):e008597. PubMed ID: 34807713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
    Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C
    ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
    Zile MR; Gottdiener JS; Hetzel SJ; McMurray JJ; Komajda M; McKelvie R; Baicu CF; Massie BM; Carson PE;
    Circulation; 2011 Dec; 124(23):2491-501. PubMed ID: 22064591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial.
    Jering K; Claggett B; Redfield MM; Shah SJ; Anand IS; Martinez F; Sabarwal SV; Seferović PM; Kerr Saraiva JF; Katova T; Lefkowitz MP; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2021 May; 9(5):386-397. PubMed ID: 33714741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction.
    Burke MA; Katz DH; Beussink L; Selvaraj S; Gupta DK; Fox J; Chakrabarti S; Sauer AJ; Rich JD; Freed BH; Shah SJ
    Circ Heart Fail; 2014 Mar; 7(2):288-99. PubMed ID: 24365774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
    Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
    Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
    Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
    Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 306.